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ABSTRACT
The Vitek 2 system was compared with conven-
tional assimilation, fermentation and morpholo-
gical methods for its ability to identify yeast
isolates from among 151 clinical specimens and 16
known type culture or quality control strains. An
unequivocal identification was obtained for 155
(92.8%) isolates, with low discrimination for nine
(5.4%) and false identification for three (1.8%)
isolates. All isolates of Candida albicans, Candida
glabrata and Candida krusei were identified cor-
rectly. It was concluded that the Vitek 2 system
offers an excellent alternative for the identification
of yeasts in a clinical laboratory.
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Yeasts have gained increasing importance in
recent decades as aetiological agents of invasive
infections in immunocompromised and other
critically-ill patients [1–3]. Simultaneously, the
proportion of Candida spp. other than Candida
albicans has increased, including the fluconazole-
resistant species Candida glabrata and Candida
krusei [2,4–6]. Therefore, identification of yeasts
to the species level has become important in
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clinical laboratories, especially when isolates from
invasive infections are involved. The Vitek 2
system (bioMe´rieux, Marcy l’Etoile, France) is an
automated instrument for the identification and
susceptibility testing of microorganisms. In the
present study, the Vitek 2 system was compared
with conventional methods for the identification
of yeasts in clinical specimens.
In total, 167 isolates were included in the study.
Of these, 98 (58.7%) were blood culture isolates,
eight (4.8%) were from other deep infections, 45
(26.9%) were isolates from superficial sites, with
about half of these being isolated from the
surveillance cultures of immunocompromised
patients, and 16 (9.6%) were known type culture
strains or strains from external quality culture
distributions. Only one isolate per patient and
infectious episode was included.
The isolates were identified by conventional
methods, as described by Barnett et al. [7]. Plate
assimilation tests (auxanograms) for carbon use
were performed with the following 28 com-
pounds: glucose, galactose, L-sorbose, D-ribose,
D-xylose, L-arabinose, D-arabinose, L-rhamnose,
sucrose, maltose, trehalose, a-methyl-D-glucoside,
cellobiose, salicin, melibiose, lactose, raffinose,
melezitose, glycerol, erythritol, ribitol, D-glucitol,
D-mannitol, galactitol, myoinositol, DL-lactic acid,
DL-succinic acid, and citric acid. Plate assimilation
tests for nitrogen use were performed with pep-
tone and potassium nitrate. Fermentation tests in
Durham tubes were performed with the following
seven sugars: glucose, galactose, maltose, sucrose,
trehalose, lactose and raffinose. Yeast isolates were
also analysed with the broth test for urea hydro-
lysis. Microscopy of growing cultures was
performed to examine the appearance of non-
filamentous vegetative cells and filamentous
growth. With some isolates, the ability to grow at
37C, 40C and 45C was also tested. The results
were interpreted using the tables of Barnett et al.
[7].
Vitek 2 yeast cards (ID-YST) were inoculated
with 24–48-h cultures and were analysed using the
Vitek 2 instrument (database v.3.01) according to
the instructions of the manufacturer. The Vitek 2
system identified 155 (92.8%) of the isolates
correctly (Table 1). Of these, 101 were placed in
the identification category ‘excellent’, 44 in the
category ‘very good’, eight in the category ‘good’,
and two in the category ‘acceptable’. In total, 136
(93.8%) of 145 Candida isolates, including all
C. albicans, C. glabrata and C. krusei, were identi-
fied correctly. A low discrimination result was
obtained with nine (5.4%) isolates, two of which
were identified correctly following use of the
additional tests suggested by Vitek 2; thus, the
final number of correct identifications was 157
(94.0%). Three (1.8%) isolates were misidentified,
comprising an isolate of Candida guilliermondii
identified as Candida parapsilosis, an isolate of
Candida zeylanoides identified as Candida famata ⁄
Candida valida, and an isolate of Trichosporon spp.
identified as Cryptococcus humicolus. When the test
was repeated, the C. guilliermondii isolate was
identified correctly with ‘good identification’; thus
technical error or low reactivity following poor
growth might have caused the first erroneous
result. The low discrimination results were
caused, in part, by missing reactions, and not by
erroneous positive reactions. This emphasises the
need to control the quality and strength of the
inocula carefully.
The present results were better than those
obtained by Graf et al. [8], who reported unequi-
vocal identification for 87.6% of isolates when
using ID 32 C as the reference method. The
number of misidentifications (1.7%) was compar-
able with the results in the present study, but the
number of low discriminations was greater. This
could have been caused partly by the selection of
Table 1. Results obtained for the identification of 167
yeast isolates using the Vitek 2 system in comparison with
conventional identification methods
Conventional identification n
Vitek 2 identification
Unequivocal
identification
Low
discrimination
False
identification
Candida albicans 48 48 0 0
Candida dubliniensis 2 2 0 0
Candida glabrata 23 23 0 0
Candida guilliermondii 7 6 0 1
Candida inconspicua 2 0 2 0
Candida kefyr 1 1 0 0
Candida krusei 10 10 0 0
Candida lipolytica 2 1 1 0
Candida lusitaniae 7 6 1 0
Candida parapsilosis 22 21 1 0
Candida pelliculosa 2 2 0 0
Candida rugosa 7 5 2 0
Candida tropicalis 10 10 0 0
Candida zeylanoides 2 1 0 1
Cryptococcus neoformans 5 4 1 0
Geotrichum candidum 2 2 0 0
Malassezia furfur 1 0 1 0
Rhodotorula glutinis 1 1 0 0
Saccharomyces cerevisiae 10 10 0 0
Trichosporon mucoides 2 2 0 0
Trichosporon spp. 1 0 0 1
Total 167 155 9 3
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strains, but the improved performance in the
present study may also be a result of the devel-
opment of the Vitek 2 database. Identification of
C. guilliermondii and Candida lusitaniae was prob-
lematic, both in the study by Graf et al. [8] and in
the present study, whereas all C. glabrata isolates
were identified without difficulty. This is in
contrast to the study by Massonet et al. [9], in
which most difficulties were encountered with
C. glabrata. The reason for this discrepancy is
unknown. As in the study by Graf et al. [8], the
present database was unable to separate Candida
inconspicua and Candida norvegensis.
Conventional identification methods are still
considered to be the reference standard for the
identification of yeast isolates, but are laborious
and time-consuming, and are suited better to
research than to clinical laboratories. The Vitek 2
system identifies most clinically important Candida
spp. reliably within 15 h, and appears to be an
excellent alternative identification method for clin-
ical laboratories performing fungal diagnostics.
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ABSTRACT
Brucella melitensis is highly pathogenic and con-
stitutes a serious risk to public health. In Argen-
tina, biovar 1 has been isolated from infected
animals, but the Rev.1 strain vaccine is not
authorised for use. This report describes nine
atypical B. melitensis isolates obtained from hu-
mans. These isolates grew slowly, produced small
colonies and were susceptible to penicillin and
dyes, similar to the B. melitensis Rev.1 vaccine
strain, but were inhibited by streptomycin
2.5 mg ⁄L. The isolation of such atypical B. meli-
tensis variants has never been reported from
animals in Argentina, and could indicate the
emergence of a new mutant variant.
Keywords Brucella melitensis, identification, pheno-
typic characteristics, Rev.1 vaccine, variant
Corresponding author and reprint requests: N. E. Lucero,
Brucellosis Laboratory, Administracio´n Nacional de Laborato-
rios e Institutos de Salud Dr C.G. Malbra´n (ANLIS), Avda.
Velez Sarsfield 563, 1281 Buenos Aires, Argentina
E-mail: nidia@elsitio.net
Research Notes 593
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 576–596
